Last quarter (Q3 2023), Reviva Pharmaceuticals Holdings's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Reviva Pharmaceuticals Holdings's net income was $-10.49M. See Reviva Pharmaceuticals Holdings’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 8.27M	$ 24.31M	$ 10.10M	$ 2.43M	$ 376.86K
Operating Income	$ -23.82M	$ -24.31M	$ -10.10M	$ -2.43M	$ -376.86K
Net Non Operating Interest Income Expense	$ 441.38K	-	$ -2.41K	$ -1.35M	$ -469.17K
Other Income Expense	$ 777.03K	$ 11.91K	$ -1.59M	-	-
Pretax Income	$ -37.62M	$ -24.32M	$ -8.52M	$ -3.78M	$ -846.03K
Tax Provision	$ 23.94K	$ 20.78K	$ 6.00K	$ 800.00	$ 800.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -24.18M	$ -24.34M	$ -8.52M	$ -3.78M	$ -846.83K
Basic EPS	$ -1.67	$ -1.25	$ -0.58	$ -1.24	$ -0.31
Diluted EPS	$ -1.29	$ -1.25	$ -0.58	$ -1.24	$ -0.31
Basic Average Shares	$ 87.82M	$ 19.52M	$ 14.79M	$ 3.06M	$ 2.77M
Diluted Average Shares	$ 68.30M	$ 19.52M	$ 14.79M	$ 3.06M	$ 2.77M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 8.27M	$ 24.31M	$ 10.10M	$ 2.43M	$ 376.86K
Net Income From Continuing And Discontinued Operation	$ -37.65M	$ -24.34M	$ -8.52M	$ -3.78M	$ -846.83K
Normalized Income	$ -18.10M	$ -19.21M	-	$ -3.78M	$ -846.83K
Interest Expense	-	-	-	$ 1.45M	$ 469.37K
EBIT	$ -37.87M	$ -24.32M	$ -8.51M	$ -2.33M	$ -376.66K
EBITDA	$ -37.87M	$ -24.32M	$ -8.51M	$ -2.33M	$ -376.01K

Currency in USD

Reviva Pharmaceuticals Holdings Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing